75 related articles for article (PubMed ID: 9380591)
21. Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy?
Potters L; Calugaru E; Jassal A; Presser J
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1014-9. PubMed ID: 16682144
[TBL] [Abstract][Full Text] [Related]
22. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
[TBL] [Abstract][Full Text] [Related]
23. Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Cancer J; 2001; 7(5):404-12. PubMed ID: 11693899
[TBL] [Abstract][Full Text] [Related]
24. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.
Lee HK; Adams MT; Motta J
Brachytherapy; 2008; 7(1):17-21. PubMed ID: 18201939
[TBL] [Abstract][Full Text] [Related]
25. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103.
Rivard MJ; Butler WM; Devlin PM; Hayes JK; Hearn RA; Lief EP; Meigooni AS; Merrick GS; Williamson JF
Brachytherapy; 2007; 6(1):34-7. PubMed ID: 17284383
[TBL] [Abstract][Full Text] [Related]
26. Long-term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated.
Talcott JA; Clark JA; Stark PC; Mitchell SP
J Urol; 2001 Aug; 166(2):494-9. PubMed ID: 11458054
[TBL] [Abstract][Full Text] [Related]
27. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
28. Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer.
Teloken PE; Ohebshalom M; Mohideen N; Mulhall JP
J Urol; 2007 Dec; 178(6):2521-5. PubMed ID: 17937948
[TBL] [Abstract][Full Text] [Related]
29. High-dose brachytherapy for treating prostate cancer: nursing considerations.
Colella J; Scrofine S
Urol Nurs; 2004 Feb; 24(1):39-44, 52. PubMed ID: 15054909
[TBL] [Abstract][Full Text] [Related]
30. Cancer of the prostate: treatment and nursing implications.
Held JL; Osborne DM; Volpe H; Waldman AR
Oncol Nurs Forum; 1994 Oct; 21(9):1517-29. PubMed ID: 7816678
[TBL] [Abstract][Full Text] [Related]
31. Factors affecting patient selection for prostate brachytherapy: what nurses should know.
Zeroski D; Abel L; Butler WM; Wallner K; Merrick GS
Clin J Oncol Nurs; 2005 Oct; 9(5):553-60. PubMed ID: 16235582
[TBL] [Abstract][Full Text] [Related]
32. Transperineal palladium 103 prostate brachytherapy: analysis of morbidity and seed migration.
Nag S; Scaperoth DD; Badalament R; Hall SA; Burgers J
Urology; 1995 Jan; 45(1):87-92. PubMed ID: 7817484
[TBL] [Abstract][Full Text] [Related]
33. Radiation safety parameters following prostate brachytherapy.
Smathers S; Wallner K; Korssjoen T; Bergsagel C; Hudson RH; Sutlief S; Blasko J
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):397-9. PubMed ID: 10487562
[TBL] [Abstract][Full Text] [Related]
34. Teaching program for patients receiving interstitial radioactive iodine 125 for cancer of the prostate.
Champagne EE; Kane NE
Oncol Nurs Forum; 1980; 7(1):12-5. PubMed ID: 6898059
[No Abstract] [Full Text] [Related]
35. Ultrasonically guided interstitial brachytherapy for prostate cancer: care of the patient in ambulatory surgery.
Redmond MC
J Perianesth Nurs; 1998 Jun; 13(3):156-64; quiz 164-7. PubMed ID: 9801541
[TBL] [Abstract][Full Text] [Related]
36. Brachytherapy: a minimally invasive option for treating prostate cancer.
Stahlinski CR; Friedman FP; Finklestein S
Minim Invasive Surg Nurs; 1994; 8(3):106-9. PubMed ID: 7812389
[No Abstract] [Full Text] [Related]
37. Understanding stereotactic radiosurgery for intracranial tumors, seed implants for prostate cancer, and intravascular brachytherapy for cardiac restenosis.
Witt ME; Haas M; Marrinan MA; Brown CN
Cancer Nurs; 2003 Dec; 26(6):494-502. PubMed ID: 15022981
[TBL] [Abstract][Full Text] [Related]
38. Long-term potency preservation following brachytherapy for prostate cancer.
Roach M
BJU Int; 2012 Jul; 110(2):225. PubMed ID: 22734476
[No Abstract] [Full Text] [Related]
39. The more things change, the more they stay the same--or do they?
Katz A
Oncol Nurs Forum; 2013 Jan; 40(1):12-3. PubMed ID: 23269762
[TBL] [Abstract][Full Text] [Related]
40. Transperineal I-125 implant of the prostate: an accurate and less morbid procedure.
Kumar PP; Bartone FF; Taylor JE; Pelton J; Jones EO
Nebr Med J; 1982 Jul; 67(7):174-7. PubMed ID: 7121625
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
